SLDB — Solid Biosciences LLC

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Solid Biosciences LLC

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the trea… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$6.92
Market Cap$751M
Float64.0M
Shares Outstanding98.4M
Price/Sales (TTM)3.65
vs. Analyst Target+146.8% to analyst PT
Dividend RateNone
Analyst Target Price$17.08 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $3.3M -$88.3M -$3.9M -$84.4M
2021 $13.6M -$72.2M $13.6M -$69.3M
2022 $8.1M -$86.0M $8.1M -$96.9M
2023 N/A -$96.0M -$2.6M -$93.4M
2024 N/A -$125M -$2.5M -$122M
2025 N/A -$174M -$1.6M -$178M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$39.5M
Sep 2025 N/A -$45.8M
Dec 2025 N/A -$49.8M
Mar 2026 N/A -$56.7M

Ownership & Float

Insider Ownership0.8%
Institutional Ownership83.1%
Short Float13.8%
% of All Funds Holding1.53%
Number of Funds Holding126

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$7.48Near-term / short-term trend
Weekly40-Week SMA$6.14Medium-term trend
Weekly80-Week SMA$5.30Cyclical trend (business cycle)
Weekly200-Week SMA$6.19Secular trend (multi-year)
Monthly10-Month SMA$6.22Near-term monthly trend
Monthly20-Month SMA$5.40Medium-term monthly trend
Monthly40-Month SMA$5.84Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$4.90 support 1.06x 9 months ago
$3.30 support 1.42x 10 months ago
$3.10 support 6.04x 14 months ago

Historical Earnings Reactions (33 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -4.93% -0.79% 27.27% 6.52% -70.91%
1 Day -4.60% -0.26% 45.45% 23.79% -74.36%
1 Week -0.29% -1.85% 45.45% 75.63% -66.55%
2 Weeks -1.08% -1.49% 42.42% 75.82% -63.18%
1 Month 1.33% -6.14% 42.42% 103.89% -62.64%

Next earnings: May 21, 2026 (4 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-3.5%37.5%8
Feb2.8%44.4%9
Mar-10.1%33.3%9
Apr-1.6%33.3%9
May4.0%50.0%8
Jun9.7%50.0%8
Jul8.5%50.0%8
Aug-0.8%37.5%8
Sep-6.9%37.5%8
Oct-4.1%25.0%8
Nov-5.6%62.5%8
Dec25.0%50.0%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.41% 41.3% 392
Tuesday 0.10% 47.1% 429
Wednesday 0.17% 44.9% 425
Thursday -0.15% 44.5% 418
Friday 0.64% 44.7% 418

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 83.1%

Insider Transactions — Smart Summary

Total insider ownership: 0.8%

Founder-led management: Annie Ganot (Co-Founder & VP of Patient Advocacy)

12-Month Insider Activity Summary

Total Filings28
Net Value-$2.6M
Net Shares Change467,287
% of Float0.7%
C-Suite Filings23
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
Howton David T Chief Operating Officer -$165,207.486 2 N/A
Tan Kevin CFO and Treasurer -$126,699.721 2 N/A
Hanrahan Jessie Chief Regulatory Officer -$103,618.103 2 N/A
Cumbo Alexander President and CEO -$96,923.005 1 N/A
Herzich Paul Chief Technology Officer -$91,305.972 2 N/A
Ganot Ilan -$13,505.36 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-12-04 – 2025-12-04 4 4 -$117,141.64 4 C-suite
2026-01-29 – 2026-02-06 14 7 -$2.3M 12 C-suite
2026-02-18 – 2026-02-18 6 6 -$232,495.253 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-11-13 Ganot Ilan -$13,505.36 Transaction at $4.12, now +68.0%
2026-02-18 Tan Kevin CFO and Treasurer -$31,469.113 Transaction at $5.82, now +18.8%
2026-02-18 Howton David T Chief Operating Officer -$43,494.228 Transaction at $5.82, now +18.8%
2026-02-18 Herzich Paul Chief Technology Officer -$21,057.053 Transaction at $5.82, now +18.8%
2026-02-18 Hanrahan Jessie Chief Regulatory Officer -$24,073.522 Transaction at $5.82, now +18.8%
2026-02-18 Cumbo Alexander President and CEO -$96,923.005 Transaction at $5.82, now +18.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Solid Biosciences LLC (SLDB) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for SLDB on Trend Edge →